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Summary
 
To investigate the role of T cell–mediated, perforin-dependent cytotoxicity in autoimmune di-
abetes, perforin-deficient mice were backcrossed with the nonobese diabetes mouse strain. It
was found that the incidence of spontaneous diabetes over a 1 yr period was reduced from 77%
in perforin 
 
1
 
/
 
1
 
 control to 16% in perforin-deficient mice. Also, the disease onset was mark-
edly delayed (median onset of 39.5 versus 19 wk) in the latter. Insulitis with infiltration of
CD4
 
1
 
 and CD8
 
1
 
 T cells occurred similarly in both groups of animals. Lower incidence and
delayed disease onset were also evident in perforin-deficient mice when diabetes was induced
by cyclophosphamide injection. Thus, perforin-dependent cytotoxicity is a crucial effector
mechanism for 
 
b
 
 cell elimination by cytotoxic T cells in autoimmune diabetes. However, in
the absence of perforin chronic inflammation of the islets can lead to diabetogenic 
 
b
 
 cell loss by
less efficient secondary effector mechanisms.
 
I
 
nsulin-dependent diabetes mellitus (IDDM)
 
1
 
 is an au-
toimmune disease characterized by the loss of insulin-
producing pancreatic 
 
b
 
 cells. In its early and clinically silent
phase T cells and other inflammatory cells infiltrate into the
islets causing a progressive loss of 
 
b
 
 cells. When a majority
of 
 
b
 
 cells has disappeared, the lack of insulin secretion leads
to a failure of blood glucose homeostasis and diabetes.
While there is a consensus that IDDM is caused by autore-
active T cells, many other aspects of the disease are still
poorly understood. These include the breakdown of toler-
ance against islet cell antigens, the failure of mechanisms
controlling self-reactive T cells, genetic and environmental
susceptibility factors, and the molecular effector mecha-
nisms that are responsible for the elimination of 
 
b
 
 cells.
In the past it has been attempted to address this last point
by defining the role of the CD4
 
1
 
 (helper) T cells versus the
CD8
 
1
 
 (cytotoxic) T cell subset. In these studies the non-
obese diabetic (NOD) mouse strain has proved useful be-
cause it models the spontaneous initiation and the chronic
progressive course of the disease and the polygenic inherit-
ance of susceptibility genes quite well (1). Several studies
have shown that CD4
 
1
 
 and CD8
 
1
 
 primary T cells are re-
quired to adoptively transfer diabetes (2, 3). However, cloned
islet cell–reactive NOD CD4
 
1
 
 T cells were able to induce
diabetes in NOD-SCID mice in the absence of CD8
 
1
 
 T
cells (4, 5). At the time, these findings were taken as evi-
dence that both T cell subsets are required for the transfer
of diabetes with polyclonal primary T cells but that cloned
CD4
 
1
 
 T cells are able to induce diabetes independently of
CD8
 
1
 
 T cells, given high numbers and specificity.
On the other hand, a cytofluorometric study of islet-
infiltrating leukocytes has shown that CD8
 
1
 
 T cells infil-
trated into the pancreas of young, prediabetic NOD mice
earlier than CD4
 
1
 
 T and B cells (6). Similarly, in a pancreas
from a human patient who had died only a month after di-
agnosis of diabetes the islet-infiltrating T cells consisted
mainly of the CD8
 
1
 
 subset (7). Several recent studies fur-
ther supported the crucial role of CD8
 
1
 
 T cells in diabetes
of NOD mice: 
 
b
 
2
 
-microglobulin–negative and hence CD8
 
1
 
T cell–deficient NOD mice developed neither insulitis nor
diabetes (8–11). Also, depletion of CD8
 
1
 
 T cells by anti-
body treatment at 2–5-wk after birth prevents insulitis de-
velopment and also abrogates the ability of CD4
 
1
 
 T cells to
induce insulitis (12). Finally, CD8
 
1
 
 T cell clones from NOD
mice that were generated by restimulation with transgenic
islet cells expressing the costimulatory molecule B7.1 were
able to transfer diabetes to irradiated NOD and NOD-SCID
mice (13). These findings clearly demonstrated that CD8
 
1
 
T cells are not only responsible for the lysis of 
 
b
 
 cells in the
late effector phase, but that they also may have a role in the
early induction phase by affecting the properties of autore-
active CD4
 
1
 
 T cells. Perforin-deficient mice lack a major
 
1
 
Abbreviations used in this paper:
 
 GP, glycoprotein; IDDM, insulin-depen-
dent diabetes mellitus; LCMV, lymphocytic choriomeningitis virus;
NOD, nonobese diabetic.
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pathway of T cell–mediated cytotoxicity and NK cell–
mediated cytotoxicity (14–18). Since perforin-deficient
mice have no defect in activation and proliferation of T
cells and generate normal B cell responses (14), they are
well suited to directly address the role of cytotoxicity in
vivo. We have previously crossed perforin-deficient mice
with transgenic mice expressing glycoprotein (GP) of lym-
phocytic choriomeningitis virus (LCMV) in the pancreas.
Infection with LCMV triggers an acute virus-specific im-
mune response which induces insulitis and diabetes in per-
forin-expressing transgenic mice by day 10 after infection
(19). In contrast, LCMV-GP transgenic perforin-deficient
mice did not develop diabetes, although they developed
marked insulitis (20). These findings indicated that per-
forin-dependent cytotoxicity is not required for the initia-
tion of insulitis but is crucial for the destruction of 
 
b
 
 cells in
the later effector phase. However, there was the possibility
that these findings were specific to this model system, since
LCMV induces a very strong cytotoxic immune response
and, unlike human diabetes, the diabetes develops very
acutely without chronic long-term insulitis. It was there-
fore of interest to test the role of perforin-dependent cyto-
toxicity in the NOD mouse model, where the spontaneous
onset and the chronic inflammation of the pancreatic islets
are more similar to the human disease. In addition, we sur-
mised that the slower course of diabetes in the NOD
mouse may reveal additional perforin-independent effector
mechanisms, which may be masked during the very acute
progression of diabetes in the LCMV-GP transgenic model.
We report here that diabetes developed only with greatly
reduced incidence and delayed onset in perforin-deficient
NOD mice. This shows that perforin-dependent cytotox-
icity is the main effector mechanism accounting for 
 
b
 
 cell
loss in the NOD mouse but also indicates that one or sev-
eral perforin-independent mechanisms, possibly involving
Fas, can cause diabetes with reduced efficiency.
 
Materials and Methods
 
Breeding of Perforin-deficient NOD Mice.
 
Perforin-deficient mice
of the C57BL/6 strain have been previously described (14).
These mice were backcrossed for seven generations with NOD
mice (provided by Hans Acha-Orbea, Institute of Biochemistry,
University of Lausanne, Epalinges, Switzerland). At each back-
cross generation, heterozygous mice were identified by PCR
analysis for further breeding. In addition, the H-2
 
g7
 
 complex,
which contains the I-A
 
g7
 
 locus and is strongly associated with dia-
betes susceptibility in the NOD strain, was enriched by screening
at the second backcross generation for the absence of the K
 
b
 
 allele
by flow cytofluorometry of blood cells with the antibody B8-24-3.
At the third generation, the second strongest susceptibility locus
 
Idd3
 
 was enriched by PCR screening as previously described for
the microsatellite marker D3Nds1 (21). In brief, the microsatellite
marker was amplified by PCR from genomic DNA with primers
5
 
9
 
-GGA TCT GGC ACC TCC AGG G-3
 
9
 
 and 5
 
9
 
-TAT GTT
GCC TTG GCA AAT AGA TG-3
 
9
 
. The reaction product was
resolved on a 5% Nusieve agarose gel (fragment size: NOD
 
.
 
C57BL/6; FMC BioProducts, Rockland, ME). Littermate con-
trols were used in all experiments.
 
Genotyping of the Perforin Allele.
 
The perforin genotype was
determined with PCR and two different primer pairs on DNA
prepared from tail biopsies. The first pair (5
 
9
 
-TTT TTG AGA
CCC TGT AGA CCC A-3
 
9
 
, 5
 
9
 
-GCA TCG CCT TCT ATC
GCC TTC T-3
 
9
 
) yields a band of 665 bp for the mutated and is
negative for the wild-type allele. The second pair (5
 
9
 
-CCG GTC
CTG AAC TCC TGG CCA A-3
 
9
 
, 5
 
9
 
-CCC CTG CAC ACA
TTA CTG GAA G-3
 
9
 
) yields a 300-bp fragment for the wild-
type and a 1,300-bp fragment for the mutated allele.
 
Cytofluorometry.
 
T lymphocyte marker expression was ana-
lyzed by incubating spleen cell suspensions with PE-conjugated
CD8-specific and FITC-conjugated CD4-specific antibodies (Phar-
Mingen, San Diego, CA). After washing, the cell suspensions were
analyzed on a FACScan
 
Ò
 
 flow cytometer (Becton Dickinson,
Mountain View, CA) using logarithmic scales. Viable lympho-
cytes were gated for by a combination of forward light scatter and
90
 
8
 
 side scatter.
 
Measurement of Blood Glucose.
 
The glucose concentration in
blood obtained from a tail vein was measured using Haemo-Glu-
cotest strips (Boehringer Mannheim, Mannheim, Germany).
 
Induction of Diabetes by Injection of Cyclophosphamide.
 
6 mg of
cyclophosphamide (Sigma Chemical Co., St. Louis, MO) was in-
jected i.p. into 10–12-wk-old mice on day 0. If the first injection
failed to produce diabetes, 6 mg of cyclophosphamide was again
injected on day 14.
 
Immunohistochemistry.
 
Pancreata were immersed in HBSS and
snap-frozen in liquid nitrogen. Cryostat sections (5 
 
m
 
m) of tissue
were cut and fixed in cold acetone. Sections were incubated with
rat anti–mouse monoclonal antibodies YTS191.1 (anti-CD4) and
YTS169.4.2 (anti-CD8) (22). Alkaline phosphatase–labeled goat anti–
rat immunoglobulin antibodies, followed by alkaline phosphatase–
labeled donkey anti–goat immunoglobulin antibodies (Tago, Inc.,
Burlingame, CA) were used as secondary reagents. The substrate for
the red color reaction was naphtol AS-BI phosphate/New Fuchsin.
Insulin was detected on paraffin-embedded formalin-fixed tis-
sues with an insulin-specific guinea pig antiserum (Dako A/S,
Glostrup, Denmark). Primary antibodies were detected by an in-
direct immunoenzymatic staining procedure with biotinylated
antiimmunoglobulin antibodies (Zymed, San Francisco, CA) and
streptavidin-conjugated horseradish peroxidase (Dako A/S). The
red color signal was obtained by developing with aminoethylcar-
bazole (Sigma Chemical Co.).
 
Measurement of the Volume Density of Islets in the Pancreas.
 
Islets
are more frequent in the head of the pancreas than in the tail.
Thus, the head of the pancreas was fixed in formaldehyde and cut
in sections at eight consecutive levels each 100 
 
m
 
m apart. The
volume density was determined according to the Delesse princi-
ple by calculating the ratio of the sum of the islet areas to the sum
of the section areas (23). Islet and section areas were determined
by computer-assisted morphometry on a microscope equipped
with a video camera. The results are given as the mean of the vol-
ume density from several individual mice together with the SEM.
 
Statistical Analysis.
 
The time course of spontaneous diabetes
onset in normal control, heterozygous, and perforin-deficient
NOD mice was analyzed using Kaplan-Meier curves. The curves
were tested for significance by log-rank tests. All statistical proce-
dures were performed with the lifetest program of the SAS statis-
tical software package (SAS Institute, Inc., Cary, NC).
 
Results
 
Frequency of CD4
 
1
 
 and CD8
 
1
 
 T Cells in Perforin-deficient
NOD Mice.
 
We have previously shown that T cells from 
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perforin-deficient C57BL/6 mice have no defect in matu-
ration, activation, or proliferation (14). To exclude the possi-
bility that backcrossing with the NOD strain revealed a de-
fect in T lymphocyte maturation, we checked for the presence
of CD4
 
1
 
 and CD8
 
1
 
 T cells in the spleens of 8-wk-old
NOD mice. It was found that CD4- and CD8-expressing
T lymphocytes were present at comparable percentages in
normal control, heterozygous, and perforin-deficient NOD
mice, indicating that the lack of perforin did not affect T lym-
phocyte development in the NOD strain (data not shown).
 
Similar Development of Insulitis in Control and Perforin-defi-
cient NOD Mice.
 
A hallmark of the NOD mouse model
system for IDDM is the progressive infiltration of mononu-
clear cells into the islets. Inflammatory islet-infiltrating
mononuclear cells start to appear at the age of 5 wk in most
NOD mice. Histologic analysis in 8-wk-old heterozygous
and perforin-deficient mice revealed varying degrees of in-
sulitis but mostly periinsulitis in both types of mice with lit-
tle islet cell damage detectable in heterozygous and per-
forin-deficient mice (see Fig. 2 
 
A
 
). At 55 wk of age, islets
of perforin-expressing NOD mice which had not suc-
cumbed to diabetes were strongly infiltrated by mononu-
clear cells and often displayed little or no endocrine tissue.
Since diabetes only develops when 
 
.
 
90% of islet tissue is
lost, the mice were still normoglycemic. In nondiabetic
perforin-deficient mice severe insulitis had developed as
well, but more frequently than in control NOD mice the
infiltrates were associated with patches of endocrine tissue.
Sections that were stained by immunohistochemistry for
the lymphocyte surface markers CD4 and CD8 revealed
that the mononuclear infiltrate in both groups of mice con-
tained similar proportions of CD4
 
1
 
 and CD8
 
1
 
 T cells,
with CD4
 
1
 
 outnumbering the CD8
 
1
 
 cells in both groups
(see Fig. 2 
 
A
 
).
To quantitate the development of insulitis, 20–40 islets
from individual 9–12-wk-old female NOD mice were as-
sessed for the severity of insulitis. We found considerable
variability in the degree of insulitis in individual mice with
no significant difference between normal control, het-
erozygous, and perforin-deficient mice (Fig. 1 
 
A
 
). Thus,
perforin-dependent cytotoxicity is not required for the
breakdown of self tolerance nor ignorance in NOD mice,
which causes the infiltration of T cells into the islets.
 
Lack of Perforin Leads to Reduced Incidence and Delayed On-
set of Diabetes.
 
The role of perforin-dependent cytotoxic-
ity in the diabetes disease process was evaluated by observ-
ing the incidence of spontaneous diabetes in female mice
over a period of 55 wk (Fig. 1 
 
B
 
). In normal control NOD
mice diabetes progressively developed between 15 and 30
wk (median: 19 wk) of age, and after that the incidence
plateaued at 77% (
 
n
 
 
 
5
 
 13). Heterozygous mice displayed a
slightly delayed pattern of disease onset (median: 27 wk)
with an incidence of diabetes at the end of the observation
period of 67% (
 
n
 
 
 
5
 
 27), possibly indicating a weak gene
dosage effect (
 
P
 
 
 
5
 
 4.75%). In contrast, in perforin-deficient
mice, disease incidence was reduced to 16% (
 
n
 
 
 
5
 
 21, 
 
P
 
 
 
5
 
0.01%) and diabetes occurred only between 35 and 41 wk
(median: 39.5 wk) of age. In all diabetic perforin-deficient
Figure 1. Development of insuli-
tis and diabetes. (A) Semiquantita-
tive assessment of insulitis in 9–12-
wk-old normal control (1/1), het-
erozygous (1/0), or perforin-defi-
cient (0/0) NOD mice. 20–40 ran-
domly chosen islets/mouse were
assessed on pancreas sections stained
with hematoxylin and eosin. Insulitis
was classified as either periinsulitis,
moderate insulitis, or strong insulitis.
Periinsulitis indicates a weak periph-
eral inflammatory infiltrate that does
not penetrate the islet tissue, moder-
ate insulitis indicates an infiltrate
,50% of the islet area, and strong
insulitis indicates an infiltrate .50%
of the islet area. The results are given
as percentage of islets per total islets
scored for each mouse. Sections
from three perforin 1/1, six perforin 1/0, and six perforin 0/0 mice
were assessed. (B) Delayed onset and reduced incidence of spontaneous
diabetes in perforin-deficient mice. Normal control (1/1, n 5 13), het-
erozygous (1/0, n 5 27), and perforin-deficient (0/0, n 5 25) female
NOD mice (seventh generation backcross, littermates) were observed
over a period of 55 wk. Animals were considered diabetic if two succes-
sive blood glucose measurements at least 1 d apart yielded values .17
mM. (C) Analysis of spontaneous diabetes in perforin-deficient mice. In-
sulin dependence in perforin-expressing and perforin-deficient diabetes
mice. Newly diagnosed diabetic mice were injected with 1 IU of human
recombinant insulin s.c. into the flank and blood glucose levels were
monitored subsequently. Normal NOD and heterozygous mice were 25
and 33 wk old, respectively, whereas diabetic perforin-deficient mice
were both 41 wk old. Blood glucose levels from individual mice are
shown. The experiment was repeated twice with similar results.992 Perforin-dependent Cytotoxicity in Autoimmune Diabetes
Figure 2. Histological analysis of pancreatic islets. (A) Comparable degree of insulitis
in pancreata of perforin-competent (1/0, top) and perforin-deficient (0/0, bottom)
NOD mice. Pancreas sections from young (8-wk-old) and adult (55-wk-old) mice
were stained with either hematoxylin and eosin (HE) or used for immunohistochemis-
try with CD4- or CD8-specific antibodies. Antibody binding resulted in red staining.
(B) Presence of insulin-containing b cells in the islets of diabetic perforin-deficient
mice. Sections from a 30-wk-old heterozygous and a 41-wk-old perforin-deficient di-
abetic NOD mouse were stained either with hematoxylin and eosin (HE) or with in-
sulin-specific antibodies (red staining). Arrowheads in the left panel indicate reddish,
eosinophilic dying islet cells. (C) Pancreatic islets of diabetic heterozygous and per-
forin-deficient NOD mice (both 7–10 wk old) after injection with cyclophosphamide.
Diabetes occurred in the heterozygous mice 13 d after the first injection with 6 mg cy-
clophosphamide and in the perforin-deficient mouse 16 d after the second injection.
Pancreas sections were either stained with hematoxylin and eosin (HE) or antiinsulin
antibodies (red staining). Note the presence of insulin-containing b cells in the diabetic perforin-deficient NOD mouse and their lower intensity of insulin
staining compared to islets from a healthy, untreated control C57BL/6 mouse.
mice, blood sugar rose to values comparable to values of di-
abetic control mice (28–44 mM) and did not spontaneously
revert to lower values. Diabetes incidence in male perforin-
expressing control mice was low (,20%). No diabetes was
observed in perforin-deficient male NOD mice (data not
shown).
To test whether the diabetes observed in perforin-defi-
cient mice was insulin-dependent, spontaneously diabetic
NOD mice were injected with 1 IU of insulin (Fig. 1 C).
In perforin-expressing as well as perforin-deficient NOD
mice insulin administration drastically lowered blood sugar
levels 15 min after s.c. injection and normoglycemia was
reached within 60 min after injection. Thus, diabetes in
perforin-deficient mice is caused by a lack of insulin, either
due to the loss of b cells or an inability of b cells to secrete
sufficient amounts of insulin.
Histological Analysis of Pancreata from Diabetic Mice. Histo-
logical analysis of pancreatic sections from diabetic animals993 Kägi et al.
revealed that in contrast to diabetic perforin-competent
NOD mice, in which b cells were not detected, hematox-
ylin and eosin–stained sections from diabetic perforin-defi-
cient NOD mice showed endocrine tissue which contained
insulin-expressing  b cells (Fig. 2 B). To investigate the
question whether these b cells represent a low or a high
percentage of the b cells present in healthy control mice,
i.e., whether perforin-deficient mice were able to eliminate
b cells, we compared the amount of endocrine tissue be-
tween young NOD mice and diabetic perforin-deficient
mice. Representative sections were prepared from the head
of the pancreas, where islets are more numerous than in the
tail, and the volume density of endocrine islet tissue was
calculated. The volume density of young 7-wk-old NOD
mice was 1.18 6 0.10% (n 5 2). In contrast, perforin-defi-
cient diabetic mice had a drastically reduced volume den-
sity of 0.010 6 0.002% (n 5 3). Thus, diabetes in perforin-
deficient mice was caused by a loss of b cells, indicating
that alternative mechanism can cause b cell damage in the
absence of perforin-dependent cytotoxicity. This notion
was also supported by the observation of occasional cells in
islets from diabetic perforin-deficient mice with a promi-
nent eosinophilic cytoplasm and condensed nuclei. The
prominent cytoplasms indicated that these cells were b cells
whereas eosinophilic staining and condensed nuclei are his-
tological signs of cell death (Fig. 2 B).
Induction of Diabetes by Injection with Cyclophosphamide.
Injection of cyclophosphamide induces diabetes in NOD
mice (24). The underlying mechanism of this effect is not
completely clear, but it has been found that a single injec-
tion of cyclophosphamide induces a temporary reduction
of CD41 and CD81 T lymphocytes (25). After recovery of
the T cell compartment diabetes develops in a high per-
centage of young NOD mice of both sexes, but not in
other nondiabetes–prone strains (1). Diabetes induced by
cyclophosphamide is dependent on T cells (26, 27) and is
probably caused by a yet poorly understood deregulation of
the T cell compartment.
Cyclophosphamide was injected into 8–12-wk-old con-
trol or perforin-deficient NOD mice, with the first injec-
tion on day 0 and the second on day 14. Some of the nor-
mal control and heterozygous mice developed diabetes on
days 12–14 before the second injection, but most became
diabetic only after the second injection of cyclophospha-
mide between days 25 and 30, with incidences of 80% for
normal control and 90% for heterozygous mice at 50 d after
the first injection (Fig. 3 A). However, in perforin-defi-
cient mice diabetes occurred only between days 32 and 38
and the incidence was reduced to 18%. Whereas blood glu-
cose values in all diabetic perforin-expressing mice quickly
rose to values of 44 mM, often followed by death from ke-
toacidosis, perforin-deficient mice displayed only tempo-
rary hyperglycemia with intermediate blood glucose values
of 17 or 28 mM and eventually returned to normoglycemia
(Fig. 3 B). Histological analysis of pancreas sections from
diabetic perforin-expressing mice showed pronounced in-
sulitis and complete elimination of islet cells. In contrast, in
diabetic perforin-deficient mice secretory islet cells rich in
cytoplasm were still present despite a marked mononuclear
infiltrate. Antiinsulin immunohistochemical staining con-
firmed the absence of b cells from pancreata of diabetic
perforin-expressing mice whereas diabetic perforin-defi-
cient mice retained some insulin-containing b cells (Fig. 2
C). Thus the reduced incidence and later onset of diabetes
in perforin-deficient NOD mice in the presence of marked
insulitis confirm the finding with spontaneous diabetes and
indicate that perforin plays a crucial role in the develop-
ment of diabetes.
Figure 3. Induction of diabetes by injection of cyclophosphamide. (A) Incidence of diabetes after i.p. injection of 6 mg of cyclophosphamide on days
0 and 14 into 8–12-wk-old normal control (n 5 5), heterozygous (n 5 16), and perforin-deficient (n 5 13) mice. The experiment was repeated twice
with similar results. (B) Blood glucose values in four representative heterozygous or perforin-deficient mice from the experiment shown in A.994 Perforin-dependent Cytotoxicity in Autoimmune Diabetes
Discussion
The results of this study show that inactivation of per-
forin in NOD mice results in delayed onset and reduced
incidence of diabetes. Perforin-dependent cytotoxicity is
generally exerted by CD81 T and NK cells (14, 18). In
pancreatic islets of NOD mice, only a few NK cells have
been found; perforin expression is thus confined to infil-
trating CD81 T cells (28). That perforin-dependent cyto-
toxicity mediated by CD81 T cells is crucial in the late ef-
fector phase of diabetes in NOD mice is supported by the
following evidence. First, the incidence of spontaneous and
cyclophosphamide-induced diabetes is markedly reduced in
perforin-deficient NOD mice. Second, the low percentage
of perforin-deficient mice that developed diabetes showed
a delayed disease process with significantly later onset.
Third, in cyclophosphamide-induced diabetes, the blood
sugar levels in perforin-deficient mice only temporarily
reached diabetic levels. Finally, perforin-deficient NOD
mice developed infiltration of CD41 and CD81 T cells
into the islets comparable to those in control mice. This last
result indicates that perforin-dependent cytotoxicity is not
involved in the breakdown of tolerance and/or ignorance
towards islet antigens in the CD41 or in the CD81 T cell
subset which results in insulitis in the early stages of the dis-
ease. Therefore, the reduced incidence of diabetes in per-
forin-deficient mice is not explained by a correspondingly
reduced presence of inflammatory cells in the islets, but
rather reflects a defect at the level of the diabetogenic effec-
tor mechanism.
Backcrossing perforin-deficient mice with the NOD
strain and screening for the disrupted, C57BL/6-derived
perforin allele results in coselection of C57BL/6-derived
chromosomal regions linked to the perforin gene on chro-
mosome 10 (29). These regions may carry a diabetes sus-
ceptibility gene in the NOD mouse. Theoretically, the re-
duced incidence of diabetes in perforin-deficient mice may
be explained by the absence of a diabetes susceptibility
gene linked to the perforin locus. However, since none of
the known 13 susceptibility markers has been mapped to
chromosome 10 (30) and since in a backcross analysis no
association with diabetes was found for a marker on chro-
mosome 10 (21), this possibility is unlikely. A weak and
only barely significant (P 5 4.75%) gene dosage effect be-
tween perforin 1/1 and 1/0 mice was observed in diabe-
tes incidence. During the functional analysis of perforin-
deficient mice, gene dosage effects were observed in other
experiments as well, e.g., in the cytotoxic activity of peri-
toneal exudate lymphocytes against allogeneic fibroblast
target cells and in the control of injected syngeneic fibrosar-
coma tumor cells (14). This, together with the low abun-
dance of perforin mRNA in vivo (31), indicates that the
amount of perforin in CTLs may be a limiting factor for
certain effector functions.
Recently, absence of insulitis has been reported in b2-
microglobulin–deficient NOD mice (9–11) and in NOD
mice that were treated during an age window of 2–5 wk
after birth with CD81 T cell–depleting antibodies (12).
Transfer experiments indicated that CD81 T cells are re-
quired during that period to induce the ability to infiltrate
the pancreatic islets in CD41 T cells. It has been suggested
that b cell antigens released by CD81 T cell–mediated lysis
are required to trigger a CD41 T cell response (32). How-
ever, in perforin-deficient mice CD41 T cells infiltrate the
pancreas to a similar degree as in control mice. Thus induc-
tion of insulitis by CD41 T cells does not require the lysis
of b cells by perforin-dependent cytotoxicity. This also in-
dicates that perforin-dependent cytotoxicity is not involved
in the early initiation phase but rather in the later effector
phase, accounting for the lysis of b cells. Taken together,
the current evidence favors a model where disease progresses
in three phases. The first phase, which is required for the
development of islet-reactive CD41 T cells, is dependent
on CD81 T cells but does not require perforin. In the sec-
ond phase, CD41 T cell–dependent insulitis develops. In
the third phase, diabetes is induced as CD81 T cells lyse b
cells via perforin-dependent cytotoxicity.
The observation that b cell loss and diabetes develop in
perforin-deficient NOD mice argues for the existence of
one or several perforin-independent effector mechanisms.
However, since the increase of blood sugar in cyclophos-
phamide-induced diabetes was only temporary and since
spontaneous diabetes developed only with delayed and re-
duced incidence in the absence of perforin, these alterna-
tive mechanisms appear to be of lower efficiency. They may
act more slowly and therefore are able to induce diabetes only
in chronic situations, in which diabetes develops from insu-
litis over the course of several weeks. We recently reported
the complete absence of diabetes in perforin-deficient
transgenic mice expressing LCMV-GP in b cells of the
pancreas (20) whereas diabetes develops in control mice 10 d
after LCMV infection. This suggests that in a more acute
situation, perforin-independent mechanisms are not able to
induce diabetes, as observed in the LCMV-GP transgenic
model, or induce only temporary diabetes, as in the cyclo-
phosphamide-induced model. However, the more chronic
inflammatory process which occurs spontaneously in the is-
lets of NOD mice may allow sufficient time for alternative
mechanisms with low efficiency to cause diabetogenic b
cell damage.
We can only speculate on the molecular nature of the
mechanisms causing diabetes in perforin-deficient mice. A
possible secondary mechanism for elimination of b cells is
the elimination of b cells via the perforin-independent Fas
pathway of T cell–mediated cytotoxicity, which would re-
quire the expression of Fas by b cells. Fas expression associ-
ated with chronic inflammation has been reported in a
number of other glandular tissues including the salivary
gland and the prostate (33). Islets that are free of inflamma-
tory infiltrates do not express Fas (33, 34); however, incu-
bation with IL-1b induced Fas expression on cultured hu-
man b cells (34). Moreover, a recent publication has shown
that b cells express Fas after transfer of a b cell–specific
CD81 T cell clone (35). From the failure of Fas-deficient995 Kägi et al.
NOD-lpr mice to develop diabetes, and the accelerated di-
abetes in transgenic mice expressing Fas ligand on b cells,
this group postulated that Fas-mediated death of b cells
may be the main pathogenic mechanism in autoimmune
diabetes. However, since the lpr mutation leads to multiple
manifestations in the immune system including lymphade-
nopathy, accumulation of CD42, CD82, B2201 T cells,
and constitutive upregulation of Fas ligand on lympho-
cytes, the absence of diabetes in NOD-lpr mice could be
explained by these factors and not by the lack of Fas ex-
pression on b cells. Nevertheless, it is conceivable that b
cell elimination in perforin-deficient NOD mice is caused
by upregulation of the Fas molecule on b cells in response
to inflammatory cytokines produced by the infiltrate. Cog-
nate interaction with Fas ligand–expressing b cell–specific
CTLs could then induce b cell death. Noncognate interac-
tion with any other Fas ligand–expressing cell population
in the islets also is conceivable, as it has been suggested for
the elimination of thyrocytes in Hashimoto’s thyroiditis
(36).
Alternatively, soluble factors secreted by T cells and
other infiltrating leukocytes could account for b cell lysis.
It has been shown in vitro that IL-1 induces the formation
of nitric oxide selectively in b cells but not in a cells (37,
38). Thus the production of IL-1 by monocytes and mac-
rophages recruited into the islets by T cell–derived chemoat-
tractants may account for b cell elimination in perforin-
deficient mice. The islet toxicity of IL-1 may be potenti-
ated further by IFN-g and TNF-a, which synergistically
inhibit glucose-induced insulin release and cause islet cell
disintegration in vitro (39, 40). Neutralization of TNF-a
precludes the development of islet-reactive T cells in NOD
mice, indicating that TNF-a has a critical role in the early
development of the islet-specific autoimmune response
(41). On the other hand, IFN-g was shown to be essential
for upregulation of class I and class II MHC molecules in
the islets of LCMV-GP transgenic mice. Absence of IFN-g
completely prevented insulitis and diabetes in this model
system for diabetes (42). However, in IFN-g–deficient
NOD mice absence of IFN-g had less dramatic conse-
quences and merely led to reduced incidence and delayed
onset of diabetes, but had no consequence on insulitis (43).
These findings show that TNF-a and IFN-g seem to be
involved in the modulation of the autoreactive T cell re-
sponse and it remains to be seen whether these molecules
also mediate b cell elimination.
In two systems, CD41 T cells were found to induce dia-
betes in the absence of CD81 T cells. Cloned islet-reactive
CD41 T cells were able to transfer diabetes to NOD-SCID
recipients (4). Also, transgenic mice expressing a TCR
from the same CD41 T cell clone developed insulitis and
diabetes even when they were rendered incapable of rear-
ranging the endogenous TCR-a locus and therefore lacked
CD81 T cells (5). In both of these systems, the requirement
for CD81 T cells may be overcome by the high number of
autoreactive T cells. Similar effector mechanisms may un-
derlie both the induction of b cell loss in the absence of
perforin and diabetes induced by cloned or TCR trans-
genic CD41 T cells.
In conclusion, we have confirmed the important role of
perforin-dependent cytotoxicity in the destruction of b
cells leading to diabetes. However, our findings also show
that this role is not exclusive and that perforin-independent
mechanisms acting in situations of chronic inflammation
can cause diabetes with a slower time course and lower in-
cidence.
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